Daiichi Sankyo Company, Limited (DSKYF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Daiichi Sankyo Company, Limited (DSKYF) Healthcare & Pipeline Overview

Daiichi Sankyo Company, Limited stands out in the global pharmaceutical landscape with a robust pipeline of innovative treatments, particularly in oncology and diabetes care, supported by a strong market presence and strategic collaborations.

What Is the Investment Thesis for DSKYF?

Daiichi Sankyo Company, Limited is poised for growth driven by its strong product pipeline and strategic collaborations. The company has a market capitalization of $32.1B and a P/E ratio of 20.98, indicating a solid valuation relative to its earnings potential. Key growth catalysts include the continued success of trastuzumab deruxtecan in oncology, which is expected to drive revenue growth in the coming years. Furthermore, the company's focus on expanding its diabetes and cardiovascular product offerings aligns with global health trends, as these conditions remain prevalent. With a profit margin of 12.2% and a gross margin of 68.5%, Daiichi Sankyo demonstrates operational efficiency that supports its investment in R&D. However, potential risks include regulatory challenges and competition from generic drugs, which could impact market share and profitability.

Based on FMP financials and quantitative analysis

DSKYF Key Highlights

Market Cap of $32.1B reflects strong investor confidence in growth prospects.

• P/E ratio of 20.98 indicates attractive valuation compared to industry peers.
• Profit margin of 12.2% showcases operational efficiency and profitability.
• Gross margin of 68.5% exceeds industry average, highlighting strong pricing power.
• Dividend yield of 3.06% provides a return to shareholders amidst growth investments.

Who Are DSKYF's Competitors?

DSKYF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are DSKYF's Key Strengths?

Strong focus on R&D with a diverse product pipeline.

• Established global presence with a wide distribution network.
• High gross margins indicating strong pricing power.
• Collaborative partnerships enhancing innovation and market access.

What Are DSKYF's Weaknesses?

Dependence on a few key products for revenue generation.

• Exposure to regulatory risks in various markets.
• Challenges in maintaining competitive pricing against generics.
• Limited presence in certain emerging markets.

What Could Drive DSKYF Stock Higher?

Continued clinical trials for trastuzumab deruxtecan expected to yield positive results.

• Expansion of diabetes product offerings to meet rising global demand.
• Anticipated regulatory approvals for new therapies in key markets.
• Strategic collaborations enhancing product development capabilities.
• Launch of new consumer healthcare products aimed at expanding market reach.

What Are the Key Risks for DSKYF?

Regulatory challenges impacting the approval of new drugs.

• Competition from generic drugs affecting market share.
• Economic downturns leading to reduced healthcare spending.
• Supply chain disruptions impacting product availability.

What Are the Growth Opportunities for DSKYF?

• The company's innovative approach to cancer treatment positions it to capture significant market share as it expands its product offerings.
• The increasing prevalence of diabetes worldwide drives demand for effective management solutions.
• Strategic Collaborations: The partnership with Guardant Health to develop Guardant360 CDx enhances Daiichi Sankyo's capabilities in precision medicine. This collaboration is expected to accelerate the development of companion diagnostics, which are critical for the successful commercialization of targeted therapies.
• Emerging Markets Penetration: Daiichi Sankyo aims to expand its presence in emerging markets, where healthcare spending is increasing. By leveraging its innovative product pipeline, the company can tap into new customer segments and drive revenue growth in regions with high unmet medical needs.
• Veterinary Pharmaceuticals: The global veterinary pharmaceuticals market is projected to grow significantly, offering Daiichi Sankyo an opportunity to diversify its revenue streams. The company's existing portfolio of animal health products positions it well to capitalize on this growing segment.

What Threats Does DSKYF Face?

• Intense competition from established pharmaceutical companies.
• Regulatory challenges impacting product approvals.
• Market volatility affecting pricing and reimbursement.
• Potential for patent expirations leading to generic competition.

What Are DSKYF's Competitive Advantages?

• Strong R&D capabilities leading to a robust pipeline of innovative drugs.
• Established brand reputation and trust in the pharmaceutical industry.
• Strategic partnerships enhancing product development and market access.
• Diverse product portfolio mitigating risks associated with market fluctuations.

What Does DSKYF Do?

Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan. The company has evolved from a traditional pharmaceutical manufacturer into a global leader in the drug development sector, focusing on innovative therapies that address critical health needs. With a workforce of approximately 18,726 employees, Daiichi Sankyo operates in various therapeutic areas, including oncology, cardiovascular, and diabetes care. The company's flagship products include trastuzumab deruxtecan, an anti-cancer agent, and mirogabalin for pain management. Additionally, Daiichi Sankyo offers a range of medications for chronic conditions such as type 2 diabetes and osteoporosis, alongside a portfolio of vaccines and animal health products. The company has established strategic collaborations, notably with Guardant Health, to enhance its diagnostic capabilities. Daiichi Sankyo's commitment to research and development is evident in its extensive pipeline, which is designed to meet the evolving needs of patients worldwide. The company is well-positioned to leverage its expertise and innovation to capture growth opportunities in both established and emerging markets.

What Products and Services Does DSKYF Offer?

• Research and develop innovative pharmaceutical products for various therapeutic areas.
• Manufacture and market a diverse range of medications, including anti-cancer agents and diabetes treatments.
• Collaborate with other healthcare companies to enhance diagnostic capabilities.
• Provide vaccines and medications for animal health.
• Offer a portfolio of consumer healthcare products, including skincare and oral care items.

How Does DSKYF Make Money?

• Generate revenue through the sale of prescription medications and vaccines.
• Leverage R&D investments to develop new drugs and expand existing product lines.
• Engage in strategic partnerships to enhance product offerings and market reach.
• Utilize a global distribution network to access diverse markets and customer segments.

What Industry Does DSKYF Operate In?

The pharmaceutical industry is experiencing significant growth, driven by advancements in biotechnology and an increasing demand for innovative therapies. Daiichi Sankyo competes with major players such as Takeda Pharmaceutical Company Limited and UCB S.A., positioning itself through its focus on high-value therapeutics and strategic partnerships. The company's commitment to R&D and its diverse product portfolio allow it to adapt to changing market dynamics and capitalize on emerging opportunities.

Who Are DSKYF's Key Customers?

• Healthcare providers and hospitals seeking innovative treatment options.
• Patients requiring medications for chronic conditions such as diabetes and cancer.
• Veterinarians and animal health professionals using veterinary pharmaceuticals.
• Consumers purchasing over-the-counter healthcare products.

Daiichi Sankyo Company, Limited (DSKYF) Valuation Context

Valued at $32.1B, DSKYF is classified as a large-cap stock. Relative to its peer group, DSKYF's quantitative score of 55/100 is roughly in line with the peer average of 61/100.

DSKYF Revenue & Earnings Trend

In Q1 FY2027, DSKYF generated $3.71B in top-line revenue, marking a sequential decrease of 3.8%. The company recorded net income of $443.4M, with diluted EPS of $0.24. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, DSKYF averaged $0.22 in diluted EPS.

Company Profile

Daiichi Sankyo Company, Limited operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Chuo, Japan.

Return on equity for Daiichi Sankyo Company, Limited stands at 15.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.5%, showing how much profit it generates from its asset base. DSKYF trades at a trailing price-to-earnings ratio of 20.98, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is -1.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.4%, the inverse of the P/E and a quick read on earnings relative to price.

Daiichi Sankyo Company, Limited's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.90 places it in the grey zone, a middle ground that warrants monitoring.

Daiichi Sankyo Company, Limited has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 2122.1% above estimates on average.

DSKYF Financials

DSKYF Latest News

DSKYF Analyst Consensus

DSKYF MoonshotScore

Daiichi Sankyo Company, Limited Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources